Is serum thioredoxin-1 a useful clinical marker for malignant pleural mesothelioma?

Antioxidants and Redox Signaling

Volumn 15, Issue 3, 2011, Pages 685-689

  Maeda, Risa ^a   Tabata, Chiharu ^a   Tabata, Rie ^b   Eguchi, Ryoji ^a   Fujimori, Yoshihiro ^a   Nakano, Takashi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Hyogo Prefectural Tsukaguchi Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; REACTIVE OXYGEN METABOLITE; THIOREDOXIN 1;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MESOTHELIUM; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; ASBESTOS; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PLEURAL NEOPLASMS; PROGNOSIS; THIOREDOXINS; TUMOR MARKERS, BIOLOGICAL;

EID: 79959992883     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2011.3978     Document Type: Article

References (30)

1. Arnér ES and Holmgren A. The thioredoxin system in can-cer. Semin Cancer Biol 16: 420-426, 2006.
2. Bertoglio J, Wollman E, Shaw A, Rimsky L, and Fradelizi D. Identification of interleukin 1 alpha produced by the 3B6 human EBV-B cell line. Lymphokine Res 8: 19-24, 1989. (Pubitemid 19075255)
3. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
4. Gallegos A, Gasdaska JR, Taylor CW, Paine-Murrieta GD, Goodman D, Gasdaska PY, Berggren M, Briehl MM, and Powis G. Transfection with human thioredoxin increases cell proliferation and a dominant-negative mutant thioredoxin reverses the transformed phenotype of human breast cancer cells. Cancer Res 56: 5765-5770, 1996. (Pubitemid 26422186)
5. Holmgren A. Thioredoxin. Annu Rev Biochem 54: 237-271, 1985. (Pubitemid 15073647)
6. Hoshino T, Nakamura H, Okamoto M, Kato S, Araya S, Nomiyama K, Oizumi K, Young HA, Aizawa H, and Yodoi J. Redox-active protein thioredoxin prevents proin-flammatory cytokine-or bleomycin-induced lung injury. Am J Respir Crit Care Med 168: 1075-1083, 2003. (Pubitemid 37338936)
7. Kahlos K, Soini Y, Säily M, Koistinen P, Kakko S, Pääkkö P, Holmgren A, and Kinnula VL. Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma. Int J Cancer 95: 198-204, 2001. (Pubitemid 32477237)
8. Kamp DW and Weitzman SA. The molecular basis of as-bestos induced lung injury. Thorax 54: 638-652, 1999. (Pubitemid 29296687)
9. Kim HJ, Chae HZ, Kim YJ, Kim YH, Hwangs TS, Park EM, and Park YM. Preferential elevation of Prx I and Trx ex-pression in lung cancer cells following hypoxia and in hu-man lung cancer tissues. Cell Biol Toxicol 19: 285-298, 2003. (Pubitemid 38002149)
10. Kinnula VL, Pääkkö P, and Soini Y. Antioxidant enzymes and redox regulating thiol proteins in malignancies of hu-man lung. FEBS Lett 569: 1-6, 2004. (Pubitemid 38844583)
11. Lincoln DT, Ali Emadi EM, Tonissen KF, and Clarke FM. The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res 23: 2425-2433, 2003. (Pubitemid 36897112)
12. Nakamura H, Nakamura K, and Yodoi J. Redox regulation of cellular activation. Annu Rev Immunol 15: 351-369, 1997. (Pubitemid 27169285)
13. Nakamura H, Masutani H, and Yodoi J. Redox imbalance and its control in HIV infection. Antioxid Redox Signal 4: 455-464, 2002. (Pubitemid 34753384)
14. Nowak AK, Lake RA, Kindler HL, and Robinson BW. New approaches for mesothelioma: biologics, vaccines, gene ther-apy, and other novel agents. Semin Oncol 29: 82-96,2002. (Pubitemid 34163539)
15. Park JH, Kim YS, Lee HL, Shim JY, Lee KS, Oh YJ, Shin SS, Choi YH, Park KJ, Park RW, and Hwang SC. Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung. Respirology 11: 269-275, 2006.
16. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C, and Wali A. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353: 1564-1573, 2005. (Pubitemid 41434635)
17. Rake C, Gilham C, Hatch J, Darnton A, Hodgson J, and Peto J. Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study. Br J Cancer 100: 1175-1183, 2009.
18. Rihn BH, Mohr S, McDowell SA, Binet S, Loubinoux J, Ga-lateau F, Keith G, and Leikauf GD. Differential gene ex-pression in mesothelioma. FEBS Lett 480: 95-100, 2000.
19. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, and Hellstrom I. Me-sothelin-family proteins and diagnosis of mesothelioma. Lancet 362: 1612-1616, 2003.
20. Robinson BW and Lake RA. Advances in malignant meso-thelioma. N Engl J Med 353: 1591-1603, 2005.
21. Robinson BW, Musk AW, and Lake RA. Malignant meso-thelioma. Lancet 366: 397-408, 2005.
22. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 108: 1122-1128,1995.
23. Sasada T, Iwata S, Sato N, Kitaoka Y, Hirota K, Nakamura K, Nishiyama A, Taniguchi Y, Takabayashi A, and Yodoi J. Redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): protective effect of human thioredoxin against CDDP-induced cytotoxicity. J Clin Invest 97: 2268-2276,1996.
24. Selikoff IJ, Hammond EC, and Seidman H. Latency of as-bestos disease among insulation workers in the United States and Canada. Cancer 15: 2736-2740, 1980. (Pubitemid 11210245)
25. Soini Y, Kahlos K, Näpänkangas U, Kaarteenaho-Wiik R, Säily M, Koistinen P, Pääakkö P, Holmgren A, and Kinnula VL. Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. Clin Cancer Res 7: 1750-1757, 2001. (Pubitemid 32708645)
26. Sumida Y, Nakashima T, Yoh T, Nakajima Y, Ishikawa H, Mitsuyoshi H, Sakamoto Y, Okanoue T, Kashima K, Naka-mura H, and Yodoi J. Serum thioredoxin levels as an indi-cator of oxidative stress in patients with hepatitis C virus infection. J Hepatol 33: 616-622, 2000.
27. Tagaya Y, Maeda Y, Mitsui A, Kondo N, Matsui H, Hamuro J, Brown N, Arai K, Yokota T, Wakasugi H, and Yodoi J. ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol-reduction in the IL-2 receptor induction. EMBO J 8: 757-764, 1989. (Pubitemid 19273247)
28. Takagi Y, Mitsui A, Nishiyama A, Nozaki K, Sono H, Gon Y, Hashimoto N, and Yodoi J. Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage. Proc Natl Acad Sci USA 96: 4131-4136, 1999. (Pubitemid 29169048)
29. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Mane-gold C, Niyikiza C, and Paoletti P. Phase III study of pe-metrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644, 2003. (Pubitemid 46606305)
30. Wagner JC, Sleggs CA, and Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 17: 260-271, 1960.